Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Unicycive Therapeutics to post earnings of ($0.14) per share for the quarter.
Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). On average, analysts expect Unicycive Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Unicycive Therapeutics Stock Up 5.2 %
Shares of Unicycive Therapeutics stock traded up $0.03 during mid-day trading on Wednesday, hitting $0.64. The stock had a trading volume of 416,347 shares, compared to its average volume of 1,454,374. The firm has a 50-day moving average of $0.59 and a two-hundred day moving average of $0.60. The firm has a market cap of $76.29 million, a P/E ratio of -0.66 and a beta of 2.14. Unicycive Therapeutics has a 12-month low of $0.20 and a 12-month high of $1.16.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on UNCY shares. HC Wainwright restated a "buy" rating and issued a $7.50 target price on shares of Unicycive Therapeutics in a research report on Friday, April 11th. Guggenheim assumed coverage on shares of Unicycive Therapeutics in a research note on Monday, April 21st. They issued a "buy" rating and a $6.00 price target on the stock.
Check Out Our Latest Stock Report on Unicycive Therapeutics
Unicycive Therapeutics Company Profile
(
Get Free Report)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Read More
Before you consider Unicycive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.
While Unicycive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
